Murphy W J, Durum S K, Longo D L
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201.
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4481-5. doi: 10.1073/pnas.89.10.4481.
Growth hormone (GH) has previously been implicated in T-cell development, and here we test its efficacy in promoting T-lymphocyte engraftment in mice with severe combined immune deficiency (SCID). SCID mice receiving syngeneic thymocytes and treated with recombinant human GH (rhGH) had significantly better T-cell engraftment in their lymph nodes. Human T-cell engraftment was also strongly promoted by rhGH in SCID recipients receiving human peripheral blood lymphocytes. Additionally, although mature human cells have not been thought to enter the murine thymus, human T cells were detected in the SCID thymus after rhGH treatment. Thus, rhGH can be used to optimize long-term peripheral T-cell engraftment in these human-mouse chimeras and may also be useful clinically in treating T-cell deficiencies.
生长激素(GH)此前被认为与T细胞发育有关,在此我们测试其在促进严重联合免疫缺陷(SCID)小鼠T淋巴细胞植入方面的功效。接受同基因胸腺细胞并经重组人生长激素(rhGH)治疗的SCID小鼠,其淋巴结中的T细胞植入情况明显更好。在接受人外周血淋巴细胞的SCID受体中,rhGH也强烈促进了人T细胞的植入。此外,尽管成熟的人类细胞此前被认为不会进入小鼠胸腺,但rhGH治疗后在SCID小鼠的胸腺中检测到了人T细胞。因此,rhGH可用于优化这些人鼠嵌合体中长期外周T细胞的植入,在临床上治疗T细胞缺陷方面可能也有用处。